MCID: AST007
MIFTS: 50

Astrocytoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Astrocytoma

MalaCards integrated aliases for Astrocytoma:

Name: Astrocytoma 12 74 29 54 6 43 15 17 71
Cerebral Astrocytoma 12 71
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Astrocytic Tumor 12
Astrocytoma, Nos 12
Astrocytomas 15
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 43 D001254
SNOMED-CT 67 38713004
UMLS 71 C0004114 C0750935

Summaries for Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord.

MalaCards based summary : Astrocytoma, also known as cerebral astrocytoma, is related to glioma susceptibility 1 and gemistocytic astrocytoma. An important gene associated with Astrocytoma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1). The drugs Sirolimus and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and endothelial.

Wikipedia : 74 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 797)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 35.1 TP73-AS1 PTPN11 MIR21 MIR17HG MIR155HG IDH1
2 gemistocytic astrocytoma 34.9 LINC01089 IDH1 CCDC26
3 pilomyxoid astrocytoma 34.8 IDH1 H19 FGFR1
4 glioma 34.6 TP73-AS1 PVT1 NEAT1 MIR21 IDH1 HOXA11-AS
5 malignant glioma 32.6 PVT1 NEAT1 MIR155HG HOXA11-AS HOXA-AS3 HOTAIR
6 neuroblastoma 32.4 SNHG1 PTPN11 MIR21 MIR106A HOTAIR H19
7 medulloblastoma 32.3 PTPN11 MIR17HG IDH1 HOTAIR H19 FGFR1
8 breast cancer 32.0 TP73-AS1 PVT1 PTPN11 NEAT1 MIR21 LINC01089
9 osteogenic sarcoma 31.7 SNHG1 PVT1 NEAT1 HOXA11-AS HOTAIR H19
10 lung cancer 31.6 TP73-AS1 SNHG1 PVT1 NEAT1 MIR21 MIR17HG
11 leukemia, acute myeloid 31.6 PTPN11 MIR21 IDH1 HOTAIR FGFR1 CDKN2B-AS1
12 leukemia 31.5 PTPN11 NEAT1 HOTAIR GAS5 FGFR1 CDKN2B-AS1
13 myeloma, multiple 31.5 TP73-AS1 PVT1 PTPN11 MIR21 IDH1 HOTAIR
14 melanoma 31.4 PVT1 MIR106A HOTAIR H19 GAS5 FGFR1
15 lymphoma 31.4 PVT1 PTPN11 MIR17HG MIR155HG GAS5 FGFR1
16 hepatocellular carcinoma 31.4 TP73-AS1 SNHG1 PVT1 PTPN11 NEAT1 MIR21
17 bladder cancer 31.4 PVT1 MIR21 HOTAIR H19 GAS5 FGFR1
18 brain glioma 31.3 TP73-AS1 IDH1 GAS5
19 enchondromatosis, multiple, ollier type 31.2 PTPN11 IDH1 CCDC26
20 lung cancer susceptibility 3 31.2 MIR21 IDH1 HOTAIR H19 GAS5 FGFR1
21 renal cell carcinoma, nonpapillary 31.2 PVT1 MIR21 MIR106A HOTAIR H19 GAS5
22 colorectal cancer 31.2 SNHG1 PVT1 NEAT1 MIR21 MIR106A IDH1
23 thyroid cancer, nonmedullary, 1 31.1 HOTAIR H19 GAS5
24 nasopharyngeal carcinoma 31.1 PVT1 NEAT1 MIR21 HOTAIR H19 GAS5
25 b-cell lymphoma 31.1 PVT1 MIR21 MIR17HG HOTAIR GAS5
26 kidney cancer 31.0 PVT1 MIR21 MIR106A HOTAIR H19 GAS5
27 endometrial cancer 31.0 PTPN11 NEAT1 HOTAIR H19 GAS5 FGFR1
28 burkitt lymphoma 30.9 PVT1 NEAT1 MIR21 MIR17HG MIR155HG
29 oral squamous cell carcinoma 30.8 NEAT1 MIR21 HOTAIR H19
30 nervous system cancer 30.8 MIR21 MIR106A IDH1 CDKN2B-AS1
31 cholangiocarcinoma 30.8 NEAT1 MIR21 IDH1 H19
32 childhood oligodendroglioma 30.7 IDH1 FGFR1
33 fibrillary astrocytoma 12.7
34 juvenile pilocytic astrocytoma 12.7
35 grade iii astrocytoma 12.7
36 subependymal giant cell astrocytoma 12.7
37 melanoma-astrocytoma syndrome 12.7
38 spinal cord astrocytoma 12.4
39 cerebellar astrocytoma 12.3
40 protoplasmic astrocytoma 12.3
41 optic nerve astrocytoma 12.3
42 pilocytic astrocytoma of cerebellum 12.3
43 childhood pilocytic astrocytoma 12.3
44 juvenile astrocytoma 12.3
45 diencephalic astrocytomas 12.3
46 mixed oligodendroglioma-astrocytoma 12.3
47 desmoplastic infantile astrocytoma 12.3
48 low-grade astrocytoma 12.2
49 high-grade astrocytoma 12.2
50 childhood cerebral astrocytoma 12.2

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to Astrocytoma

Symptoms & Phenotypes for Astrocytoma

Drugs & Therapeutics for Astrocytoma

Drugs for Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 445)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
2
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
3
Trametinib Approved Phase 4 871700-17-3 11707110
4
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
5 Immunosuppressive Agents Phase 4
6 Antibiotics, Antitubercular Phase 4
7 Anti-Bacterial Agents Phase 4
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9
Ifosfamide Approved Phase 3 3778-73-2 3690
10
Tranexamic Acid Approved Phase 3 1197-18-8 5526
11
Thioguanine Approved Phase 3 154-42-7 2723601
12
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
13
Trioxsalen Approved Phase 3 3902-71-4 5585
14
Ondansetron Approved Phase 3 99614-02-5 4595
15
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
16
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
17
Donepezil Approved Phase 3 120014-06-4 3152
18
Hydroxyurea Approved Phase 3 127-07-1 3657
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
21
tannic acid Approved Phase 3 1401-55-4
22
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
23
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
24
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
25
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
26
Flucytosine Approved, Investigational Phase 2, Phase 3 2022-85-7 3366
27
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
28
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
29
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
30
Histamine Approved, Investigational Phase 3 51-45-6 774
31
Cyproheptadine Approved Phase 3 129-03-3 2913
32
Bevacizumab Approved, Investigational Phase 3 216974-75-3
33
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
34
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
35
Carvedilol Approved, Investigational Phase 2, Phase 3 72956-09-3 2585
36
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
37
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
38
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
39 Mitolactol Investigational Phase 3 10318-26-0
40
Semustine Experimental, Investigational Phase 3 13909-09-6
41 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
42 Dianhydrogalactitol Investigational Phase 3 23261-20-3
43
Isophosphamide mustard Phase 3 0
44 Hemostatics Phase 3
45 Coagulants Phase 3
46 Antifibrinolytic Agents Phase 3
47 Dihematoporphyrin Ether Phase 3
48 Liver Extracts Phase 3
49 Analgesics Phase 3
50 Nootropic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 676)
# Name Status NCT ID Phase Drugs
1 Long-term Follow-up Study to Monitor the Growth and Development of Pediatric Patients Previously Treated With Everolimus in Study CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
2 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
3 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
4 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
5 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
6 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
8 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
9 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
10 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
11 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
12 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
13 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
14 A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC) Completed NCT00789828 Phase 3 Everolimus;Placebo
15 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
16 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
17 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
18 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
19 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
20 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
21 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
22 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
23 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
24 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
25 A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone Completed NCT00088166 Phase 3 hCRF;placebo hCRF
26 An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
27 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
28 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
29 A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
30 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
31 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
32 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
33 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
34 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
35 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
36 A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
37 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Recruiting NCT03633552 Phase 3 Temozolomide
38 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
39 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
40 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
41 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
42 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
43 A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Active, not recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
44 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
45 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
46 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Not yet recruiting NCT03763422 Phase 3 Temozolomide
47 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Not yet recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib;Selumetinib Sulfate;Vincristine;Vincristine Sulfate
48 A Phase II/III Study of Non Small Cell Lung Cancer Patient With/Without Synchronous Oral Temozolomide Capsules Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost With Hippocampus Protection Not yet recruiting NCT03732482 Phase 2, Phase 3 Temozolomide capsules
49 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Not yet recruiting NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
50 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cisplatin
CISPLATIN PWDR
temozolomide

Cochrane evidence based reviews: astrocytoma

Genetic Tests for Astrocytoma

Genetic tests related to Astrocytoma:

# Genetic test Affiliating Genes
1 Astrocytoma 29

Anatomical Context for Astrocytoma

MalaCards organs/tissues related to Astrocytoma:

40
Brain, Spinal Cord, Endothelial, Bone, Pituitary, T Cells, Cerebellum

Publications for Astrocytoma

Articles related to Astrocytoma:

(show top 50) (show all 11488)
# Title Authors PMID Year
1
The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. 61 46
20219352 2010
2
Association between YKL-40 and adult primary astrocytoma. 54 61
20499402 2010
3
Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. 54 61
19876066 2010
4
Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. 54 61
20442305 2010
5
Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. 54 61
20156433 2010
6
Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas. 54 61
19775294 2010
7
Transcripts of PTTG and growth factors bFGF and IGF-1 are correlated in pituitary adenomas. 54 61
19472104 2010
8
The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. 54 61
20090845 2010
9
Alpha2-macroglobulin inhibits the malignant properties of astrocytoma cells by impeding beta-catenin signaling. 54 61
20048078 2010
10
Immunolocalization of fascin, an actin-bundling protein and glial fibrillary acidic protein in human astrocytoma cells. 54 61
19170683 2010
11
Thromboxane A2 receptor-mediated epidermal growth factor receptor transactivation: involvement of PKC-delta and PKC-epsilon in the shedding of epidermal growth factor receptor ligands. 54 61
19804825 2009
12
Genetic alterations and signaling pathways in the evolution of gliomas. 54 61
19737147 2009
13
Inflammatory protein sPLA(2)-IIA abrogates TNFalpha-induced apoptosis in human astroglioma cells: Crucial role of ERK. 54 61
19850087 2009
14
Antigen p57/Kip2 as a potential negative regulator of human astrocytoma growth. 54 61
19822429 2009
15
Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. 54 61
19434518 2009
16
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. 54 61
19731917 2009
17
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. 54 61
19554337 2009
18
J1-31 protein expression in astrocytes and astrocytomas. 54 61
19019178 2009
19
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. 54 61
20052522 2009
20
Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. 54 61
19515085 2009
21
Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. 54 61
19332645 2009
22
A reduction of epidermal growth factor receptor is involved in brefelamide-induced inhibition of phosphorylation of ERK in human astrocytoma cells. 54 61
19559020 2009
23
[Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. 54 61
19781190 2009
24
Axin induces cell death and reduces cell proliferation in astrocytoma by activating the p53 pathway. 54 61
19513548 2009
25
Natural triterpenic diols promote apoptosis in astrocytoma cells through ROS-mediated mitochondrial depolarization and JNK activation. 54 61
19543395 2009
26
Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. 54 61
19332096 2009
27
Interleukin-1beta enhances nucleotide-induced and alpha-secretase-dependent amyloid precursor protein processing in rat primary cortical neurons via up-regulation of the P2Y(2) receptor. 54 61
19317852 2009
28
[Mutation analysis of neural cell adhesion molecules in human astrocytoma]. 54 61
19587433 2009
29
Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. 54 61
18795327 2009
30
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. 54 61
19246647 2009
31
RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. 54 61
18616639 2009
32
Valproic acid enhances protein L-isoaspartyl methyltransferase expression by stimulating extracellular signal-regulated kinase signaling pathway. 54 61
19371592 2009
33
EGR-1 is regulated by N-methyl-D-aspartate-receptor stimulation and associated with patient survival in human high grade astrocytomas. 54 61
18489490 2009
34
p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. 54 61
19240607 2009
35
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. 54 61
19276385 2009
36
[Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors]. 54 61
19663312 2009
37
Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. 54 61
19473053 2009
38
Src activation and translocation from focal adhesions to membrane ruffles contribute to formation of new adhesion sites. 54 61
19066724 2009
39
Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I. 54 61
19101824 2009
40
Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors. 54 61
18498284 2008
41
TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. 54 61
18834856 2008
42
Thrombin receptor and RhoA mediate cell proliferation through integrins and cysteine-rich protein 61. 54 61
18687805 2008
43
Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma. 54 61
19204461 2008
44
Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas. 54 61
18563800 2008
45
IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. 54 61
18952587 2008
46
Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas. 54 61
18952588 2008
47
Inhibition of all-trans retinoic acid on MDM2 gene expression in astrocytoma cell line SHG-44. 54 61
18839023 2008
48
Promoter hypermethylation-mediated down-regulation of CXCL12 in human astrocytoma. 54 61
18512766 2008
49
Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds. 54 61
18664715 2008
50
Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton. 54 61
18509200 2008

Variations for Astrocytoma

ClinVar genetic disease variations for Astrocytoma:

6 (show all 21) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys)SNV Pathogenic 13336 rs121918464 12:112888210-112888210 12:112450406-112450406
2 PTPN11 NM_002834.4(PTPN11):c.227A>G (p.Glu76Gly)SNV Pathogenic 13338 rs121918465 12:112888211-112888211 12:112450407-112450407
3 PTPN11 NM_002834.4(PTPN11):c.227A>C (p.Glu76Ala)SNV Pathogenic 13339 rs121918465 12:112888211-112888211 12:112450407-112450407
4 IDH1 NM_005896.3(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
5 FGFR1 NM_023110.2(FGFR1):c.1638C>A (p.Asn546Lys)SNV Pathogenic 224896 rs779707422 8:38274849-38274849 8:38417331-38417331
6 FGFR1 NM_023110.2(FGFR1):c.1966A>G (p.Lys656Glu)SNV Pathogenic/Likely pathogenic 224897 rs869320694 8:38272308-38272308 8:38414790-38414790
7 IDH1 NM_005896.3(IDH1):c.394C>A (p.Arg132Ser)SNV Pathogenic/Likely pathogenic 375893 rs121913499 2:209113113-209113113 2:208248389-208248389
8 FGFR1 NM_015850.4(FGFR1):c.1962G>C (p.Lys654Asn)SNV Likely pathogenic 376428 rs1057519897 8:38272306-38272306 8:38414788-38414788
9 FGFR1 NM_015850.4(FGFR1):c.1630A>G (p.Asn544Asp)SNV Likely pathogenic 376429 rs1057519898 8:38274851-38274851 8:38417333-38417333
10 FGFR1 NM_015850.4(FGFR1):c.1537A>G (p.Met513Val)SNV Likely pathogenic 376430 rs1057519899 8:38275397-38275397 8:38417879-38417879
11 H3-3A NM_002107.6(H3-3A):c.83A>T (p.Lys28Met)SNV Likely pathogenic 376435 rs1057519903 1:226252135-226252135 1:226064434-226064434
12 NC_000014.9:g.38411139_38421941dupduplication Likely pathogenic 504473 14:38411139-38421941
13 IDH1 NM_005896.3(IDH1):c.394C>T (p.Arg132Cys)SNV Likely pathogenic 375891 rs121913499 2:209113113-209113113 2:208248389-208248389
14 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs)deletion Conflicting interpretations of pathogenicity 128042 rs555607708 22:29091857-29091857 22:28695869-28695869
15 TP53 NM_000546.5(TP53):c.848G>A (p.Arg283His)SNV Conflicting interpretations of pathogenicity 142324 rs371409680 17:7577090-7577090 17:7673772-7673772
16 ARID1A NM_006015.6(ARID1A):c.48_50GCC[6] (p.Pro21dup)short repeat Conflicting interpretations of pathogenicity 434329 rs748085214 1:27022939-27022940 1:26696448-26696449
17 ARID1B NM_020732.3(ARID1B):c.751T>G (p.Cys251Gly)SNV Uncertain significance 496813 rs1276300860 6:157099814-157099814 6:156778680-156778680
18 EPHA5 NM_004439.8(EPHA5):c.1043A>G (p.Asp348Gly)SNV Uncertain significance 503605 rs200932017 4:66361129-66361129 4:65495411-65495411
19 KMT2D NM_003482.3(KMT2D):c.15876G>C (p.Glu5292Asp)SNV Uncertain significance 503606 rs1365163460 12:49418638-49418638 12:49024855-49024855
20 TSC1 NM_000368.4(TSC1):c.359T>C (p.Leu120Pro)SNV Uncertain significance 523362 rs1554820262 9:135800978-135800978 9:132925591-132925591
21 PTPN11 NM_002834.4(PTPN11):c.940T>C (p.Phe314Leu)SNV Uncertain significance 620593 rs968167995 12:112915667-112915667 12:112477863-112477863

Cosmic variations for Astrocytoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM118787231 central nervous system,cerebrum,glioma,astrocytoma Grade I c.1799T>A p.V600E 7:140753336-140753336 0

Copy number variations for Astrocytoma from CNVD:

7 (show top 50) (show all 436)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13337 1 1 124300000 Loss Astrocytoma
2 13347 1 1 125000000 Deletion Astrocytoma
3 13376 1 1 2300000 Amplification AURKAIP1 Astrocytoma
4 13377 1 1 2300000 Amplification C1orf159 Astrocytoma
5 13378 1 1 2300000 Amplification CDC2L1 Astrocytoma
6 13379 1 1 2300000 Amplification CDC2L2 Astrocytoma
7 13380 1 1 2300000 Amplification CPSF3L Astrocytoma
8 13381 1 1 2300000 Amplification GNB1 Astrocytoma
9 13382 1 1 2300000 Amplification HES4 Astrocytoma
10 13383 1 1 2300000 Amplification ISG15 Astrocytoma
11 13386 1 1 2300000 Amplification MIB2 Astrocytoma
12 13387 1 1 2300000 Amplification MMP23A Astrocytoma
13 13388 1 1 2300000 Amplification NOC2L Astrocytoma
14 13389 1 1 2300000 Amplification PRKCZ Astrocytoma
15 13390 1 1 2300000 Amplification SDF4 Astrocytoma
16 13391 1 1 2300000 Amplification SLC35E2 Astrocytoma
17 13757 1 1 28000000 Deletion Astrocytoma
18 13760 1 1 28000000 Deletion Astrocytoma
19 16428 1 124300000 247249719 Gain Astrocytoma
20 16544 1 12700000 16200000 Deletion Astrocytoma
21 30468 1 243700000 249250621 Deletion AKT3 Astrocytoma
22 30469 1 243700000 249250621 Deletion SDCCAG8 Astrocytoma
23 30470 1 243700000 249250621 Deletion ZNF238 Astrocytoma
24 31970 1 32400000 34600000 Deletion Astrocytoma
25 32218 1 34600000 44100000 Deletion Astrocytoma
26 35014 1 59000000 68900000 Deletion Astrocytoma
27 36950 1 8384389 8404226 Deletion SLC45A1 Astrocytoma
28 46536 10 82000000 135374737 Loss Astrocytoma
29 48496 11 1 52900000 Loss Astrocytoma
30 67045 12 35400000 132349534 Loss Astrocytoma
31 67785 12 44600000 69800000 Gain Astrocytoma
32 75152 13 16000000 114142980 Loss Astrocytoma
33 89238 15 17000000 100338915 Gain Astrocytoma
34 97277 16 1 38200000 Loss Astrocytoma
35 97302 16 1 6300000 Amplification ABCA3 Astrocytoma
36 97303 16 1 6300000 Amplification AXIN1 Astrocytoma
37 97304 16 1 6300000 Amplification C1QTNF8 Astrocytoma
38 97305 16 1 6300000 Amplification CACNA1H Astrocytoma
39 97306 16 1 6300000 Amplification CREBBP Astrocytoma
40 97307 16 1 6300000 Amplification DNAJA3 Astrocytoma
41 97308 16 1 6300000 Amplification HMOX2 Astrocytoma
42 97309 16 1 6300000 Amplification IGFALS Astrocytoma
43 97310 16 1 6300000 Amplification MAGMAS Astrocytoma
44 97311 16 1 6300000 Amplification MAPK8IP3 Astrocytoma
45 97312 16 1 6300000 Amplification MMP25 Astrocytoma
46 97313 16 1 6300000 Amplification MPG Astrocytoma
47 97314 16 1 6300000 Amplification MRPL28 Astrocytoma
48 97315 16 1 6300000 Amplification MSLN Astrocytoma
49 97316 16 1 6300000 Amplification NME4 Astrocytoma
50 97317 16 1 6300000 Amplification NTHL1 Astrocytoma

Expression for Astrocytoma

Search GEO for disease gene expression data for Astrocytoma.

Pathways for Astrocytoma

GO Terms for Astrocytoma

Biological processes related to Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of vascular endothelial cell proliferation GO:1905564 8.62 MIR21 FGFR1

Sources for Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....